CLAIMS

1. Use of a cell population enriched for STRO-1^{bright} multipotential cells or progeny thereof in the manufacture of a medicament for reconstituting and/or repairing an intervertebral disc in a subject in need thereof.

2. Use according to Claim 1, in which the medicament is for reconstituting and/or repairing the nucleus pulposus of the intervertebral disc.

3. Use according to Claim 1 or 2, in which the STRO-1^{bright} multipotential cells are also positive for VCAM-1^{+}, THY-1^{+}, STRO-2^{+}, CD45^{+}, CD146^{+}, 3G5^{+} or any combination thereof.

4. Use according to any preceding claim, in which the STRO-1^{bright} multipotential cells are from an allogeneic source.

5. Use according to any preceding claim, in which the medicament further comprises a glycosaminoglycan (GAG).

6. Use according to Claim 5, in which the GAG is selected from the group consisting of hyaluronic acid (HA), chondroitan sulfate, dermatan sulfate, keratan sulfate, heparin, heparin sulfate, and galactosaminoglycuronglycan sulfate (GGGS).

7. Use according to any preceding claim, in which the intervertebral disc is degenerated.

8. Use according to Claim 7, in which the subject is suffering from lower back pain, age-related changes of the intervertebral disc or spondylolysis.

CLAIMS

1. Use of a cell population enriched for STRO-1^{bright} multipotential cells or progeny thereof in the manufacture of a medicament for reconstituting and/or repairing an intervertebral disc in a subject in need thereof, in which:

(i) the progeny is obtainable by expansion of said STRO-1^{bright}-enriched cell population in culture;

(ii) the progeny cells have the capacity to differentiate into different cell types; and

(iii) the medicament is suitable for intervertebral administration;

optionally in which:

(iv) the intervertebral administration comprises intradiscal administration;

(v) the intradiscal administration comprises administration into the nucleus pulposus;

(vi) the intradiscal administration comprises administration into the annulus fibrosus; or

(vii) at least 25% of the progeny cells in the composition are CC9+; the progeny cells are HLA-Class I^{+}; or the progeny cells are HLA Class II^{-}.

2. Use according to Claim 1, in which the medicament is for reconstituting and/or repairing the nucleus pulposus of the intervertebral disc.

3. Use according to Claim 1 or 2, in which the STRO-1^{bright} multipotential cells are also positive for VCAM-1^{+}, THY-1^{+}, STRO-2^{+}, CD45^{+}, CD146^{+}, 3G5^{+} or any combination thereof.

4. Use according to any preceding claim, in which the STRO-1^{bright} multipotential cells are from an allogeneic source.

5. Use according to any preceding claim, in which the medicament further comprises a glycosaminoglycan (GAG).

6. Use according to Claim 5, in which the GAG is selected from the group consisting of hyaluronic acid (HA), chondroitan sulfate, dermatan sulfate, keratan sulfate, heparin, heparin sulfate, and galactosaminoglycuronglycan sulfate (GGGS).

7. Use according to any preceding claim, in which the intervertebral disc is degenerated.

8. Use according to Claim 7, in which the subject is suffering from lower back pain, age-related changes of the intervertebral disc or spondylolysis.